Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

DURECT stock

DRRX
US2666051048
564868

Price

1.24
Today +/-
-0.05
Today %
-4.72 %
P

DURECT stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the DURECT stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the DURECT stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the DURECT stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze DURECT's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

DURECT Stock Price History

DateDURECT Price
10/4/20241.24 undefined
10/3/20241.30 undefined
10/2/20241.34 undefined
10/1/20241.36 undefined
9/30/20241.34 undefined
9/27/20241.31 undefined
9/26/20241.28 undefined
9/25/20241.22 undefined
9/24/20241.24 undefined
9/23/20241.27 undefined
9/20/20241.34 undefined
9/19/20241.37 undefined
9/18/20241.35 undefined
9/17/20241.42 undefined
9/16/20241.56 undefined
9/13/20241.51 undefined
9/12/20241.54 undefined
9/11/20241.57 undefined
9/10/20241.50 undefined
9/9/20241.46 undefined
9/6/20241.57 undefined

DURECT Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into DURECT, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by DURECT from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects DURECT’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of DURECT. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into DURECT’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing DURECT’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on DURECT’s growth potential.

DURECT Revenue, EBIT and net profit per share

DateDURECT RevenueDURECT EBITDURECT Net Income
2029e286.93 M undefined0 undefined181.1 M undefined
2028e148.03 M undefined65.11 M undefined61.42 M undefined
2027e60.55 M undefined-13.72 M undefined-12.35 M undefined
2026e23.62 M undefined-39.11 M undefined-37.04 M undefined
2025e8.74 M undefined-32.74 M undefined-41.79 M undefined
2024e8.22 M undefined-26.4 M undefined-27.54 M undefined
20238.55 M undefined-36.88 M undefined-27.62 M undefined
202219.28 M undefined-35.08 M undefined-35.33 M undefined
202113.98 M undefined-34.27 M undefined-36.27 M undefined
202030.11 M undefined-12.62 M undefined-580,000 undefined
201925.07 M undefined-19.94 M undefined-20.58 M undefined
201815.28 M undefined-23.64 M undefined-25.32 M undefined
201749.17 M undefined-2.24 M undefined-3.7 M undefined
201614.03 M undefined-32.36 M undefined-34.51 M undefined
201519.12 M undefined-20.66 M undefined-22.66 M undefined
201419.4 M undefined-21 M undefined-22.11 M undefined
201315.33 M undefined-21.16 M undefined-21.45 M undefined
201253.07 M undefined16.06 M undefined16.2 M undefined
201133.49 M undefined-18.85 M undefined-18.77 M undefined
201031.59 M undefined-23.84 M undefined-22.9 M undefined
200924.46 M undefined-30.67 M undefined-30.29 M undefined
200828.54 M undefined-31.19 M undefined-43.91 M undefined
200735.64 M undefined-24.54 M undefined-24.34 M undefined
200622.32 M undefined-31.43 M undefined-33.33 M undefined
200528.57 M undefined-15.63 M undefined-18.13 M undefined
200413.85 M undefined-24.31 M undefined-27.64 M undefined

DURECT Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0036711132822352824313353151919144915253013198882360148286
---100.0016.6757.1418.18115.38-21.4359.09-20.00-14.2929.176.4560.61-71.7026.67--26.32250.00-69.3966.6720.00-56.6746.15-57.89--187.50160.87146.6793.24
--33.3350.0057.1481.8284.6289.2986.3691.4389.2979.1787.1084.8590.5766.6768.4278.9557.1485.7186.6792.0093.3392.3189.4775.00------
00134911251932251927284810131584213232812176000000
-1-9-22-35-38-21-24-15-31-24-31-30-23-1816-21-21-20-32-2-23-19-12-34-35-36-26-32-39-13650
---733.33-583.33-542.86-190.91-184.62-53.57-140.91-68.57-110.71-125.00-74.19-54.5530.19-140.00-110.53-105.26-228.57-4.08-153.33-76.00-40.00-261.54-184.21-450.00-325.00-400.00-169.57-21.6743.92-
-1-9-20-44-37-22-27-18-33-24-43-30-22-1816-21-22-22-34-3-25-200-36-35-27-27-41-37-1261181
-800.00122.22120.00-15.91-40.5422.73-33.3383.33-27.2779.17-30.23-26.67-18.18-188.89-231.254.76-54.55-91.18733.33-20.00---2.78-22.86-51.85-9.76-67.57-608.33196.72
0.370.531.714.644.835.055.155.376.67.057.838.348.698.748.8610.3111.1711.8513.3214.5315.9817.819.9522.522.7826.26000000
--------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The DURECT Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the DURECT is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
816.6104.455.242.860.741.883.669.957.350.341.145.428.428.520.632.7292536.834.364.740.769.843.529.68
00.11.30.80.922.54.52.23.64.11.73.73.42.22.32.12.21.22.41.82.30.96.53.41.26
00000000000000000000000000
00.22.71.91.71.91.922.123.52.82.83.33.43.53.63.93.83.23.43.41.91.92.12.22
0.10.60.92.31.61.51.441.71.92.51.42.92.22.31.913.12.53.12.21.519.53.62.41.51
8.117.5109.360.24766.147.694.175.964.860.44754.837.336.428.339.438.232.545.541.771.96381.851.434.67
0.21.34.513.111.69.37.17.37.57.763.81.83.12.521.71.61.30.90.66.553.72.14.07
02.31.7182.621.317.25.510.53.71.403.21.503.41.8000001000
00000000000000000000000000
01.43.35.54.131.70.50.10.20.20.10.10.1000000000000
001.94.64.76.46.46.46.46.46.46.46.46.46.46.46.46.46.46.46.46.46.26.26.26.17
0003.42.96.35.43.62.31.30.70.81.30.80.70.70.60.50.40.41.31.30.40.40.40.28
0.2511.444.625.946.337.823.326.819.314.711.112.811.99.612.510.58.58.17.78.314.212.610.38.710.52
8.322.5120.7104.872.9112.485.4117.4102.784.175.158.167.649.24640.849.946.740.653.25086.175.692.160.145.19
                                                   
000000000000000000000000023
9.634.6165188.8193.8194.9196239.1265.9287.7321.1341.7351.3359375.7391.5401.3420.5448.4465.2488.6512529.9583.8586.4603.78
-1.3-10.6-31.5-76.4-113.6-136.3-163.9-182-215.3-239.7-283.6-313.9-336.8-355.5-339.3-360.8-382.9-405.6-440.1-443.8-468.6-489.2-489.8-526-561.4-589.01
-500-3,300-18,300-15,400-14,100-13,600-13,800-13,700-13,500-13,4001000000010000000000-14
00000000000000000000000000
7.820.7115.29766.14518.343.437.134.637.627.814.53.536.430.718.514.98.321.42022.840.157.82514.78
0.10.50.720.40.61.71.80.91.81111.31.80.711.32.11.51.62.11.71.33.11.78
0.40.82.92.42.12.62.53.94.55.55.25.36.54.945.95.155.15.54.78.37.68.67.85.77
00.20.30.62.11.30.83.97.18.210.75.910.48.71.10.60.91.21.81.51.426.30.50.222.8
00000000000000000000000000
00.10.40.70.60.50.50.20.223.60000000019.97.3000.9021.216.66
0.51.64.35.75.255.59.812.739.116.912.217.914.96.97.277.528.915.87.736.710.710.134.127.01
0.10.21.121.461.460.95837.9000000019.819.7012.620.520.319.920.600
00000000000000000000000000
0000.20.20.90.76.114.810.420.418.135.230.82.72.94.84.83.43.21.86.14.93.51.13.4
0.10.21.12.21.662.361.664.152.710.420.418.135.230.82.72.924.624.53.415.822.326.424.824.11.13.4
0.61.85.47.96.867.367.173.965.449.537.330.353.145.79.610.131.63232.331.63063.135.534.235.230.41
8.422.5120.6104.972.9112.385.4117.3102.584.174.958.167.649.24640.850.146.940.6535085.975.69260.245.19
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of DURECT provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand DURECT's financial health and stability.

Assets

DURECT's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that DURECT must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of DURECT after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into DURECT's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-1-8-19-44-37-22-27-18-33-24-43-30-22-1816-21-22-22-34-3-25-200-36-35-27
00134443222221000000000000
00000000000000000000000000
00-110-10616-39-520-6-3512-13-2128-28-461
005171001463123151387755665-855-8
00000233220000000111111112
00000000000000000000000000
0-7-14-22-31-19-22-7-9-18-9-207-17-13-15-14-20-27-1-1911-38-37-26-34
0-1-8-7-10-1-2-2-2000-2000000000000
0-16-52-1127-302013-16130-10-61431-1566124-2791519-1
0-15-44-429-292116-14151-10-51741-1566124-2791519-1
00000000000000000000000000
00850056000000000019000-10000-5
8192405003921110011110515241218201551025
8191100457038211100111102415231217191550020
--------------------------
00000000000000000000000000
7-442-3417-145-23-3-8-212-12-3-5012323-1328-6-15
-0.95-8.29-23.33-29.79-32.72-20.21-23.35-9.61-11.7-20.95-10.35-21.187.5-19.86-13.74-15.52-14.76-21.06-27.44-1.41-19.8410.94-38.91-37.5-26.39-34.47
00000000000000000000000000

DURECT stock margins

The DURECT margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DURECT. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DURECT.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the DURECT's sales revenue. A higher gross margin percentage indicates that the DURECT retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the DURECT's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the DURECT's total revenue generated. When comparing the revenue margin year over year, investors can gauge the DURECT's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the DURECT. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the DURECT's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

DURECT Margin History

DURECT Gross marginDURECT Profit marginDURECT EBIT marginDURECT Profit margin
2029e79.91 %0 %63.12 %
2028e79.91 %43.98 %41.49 %
2027e79.91 %-22.65 %-20.39 %
2026e79.91 %-165.55 %-156.81 %
2025e79.91 %-374.53 %-478.12 %
2024e79.91 %-321.23 %-335.14 %
202379.91 %-431.49 %-323.16 %
202291.8 %-181.95 %-183.25 %
202185.98 %-245.14 %-259.44 %
202095.35 %-41.91 %-1.93 %
201994.97 %-79.54 %-82.09 %
201889.27 %-154.71 %-165.71 %
201786.52 %-4.56 %-7.52 %
201662.3 %-230.65 %-245.97 %
201579.6 %-108.05 %-118.51 %
201470.72 %-108.25 %-113.97 %
201368.43 %-138.03 %-139.92 %
201291.24 %30.26 %30.53 %
201185.91 %-56.29 %-56.05 %
201086.48 %-75.47 %-72.49 %
200978.29 %-125.39 %-123.83 %
200888.19 %-109.29 %-153.85 %
200790.94 %-68.86 %-68.29 %
200685.44 %-140.82 %-149.33 %
200590.13 %-54.71 %-63.46 %
200480.29 %-175.52 %-199.57 %

DURECT Stock Sales Revenue, EBIT, Earnings per Share

The DURECT earnings per share therefore indicates how much revenue DURECT has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue DURECT earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates DURECT's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of DURECT’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating DURECT's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

DURECT Revenue, EBIT and net profit per share

DateDURECT Sales per ShareDURECT EBIT per shareDURECT Earnings per Share
2029e9.24 undefined0 undefined5.83 undefined
2028e4.77 undefined0 undefined1.98 undefined
2027e1.95 undefined0 undefined-0.4 undefined
2026e0.76 undefined0 undefined-1.19 undefined
2025e0.28 undefined0 undefined-1.35 undefined
2024e0.26 undefined0 undefined-0.89 undefined
20230.33 undefined-1.4 undefined-1.05 undefined
20220.85 undefined-1.54 undefined-1.55 undefined
20210.62 undefined-1.52 undefined-1.61 undefined
20201.51 undefined-0.63 undefined-0.03 undefined
20191.41 undefined-1.12 undefined-1.16 undefined
20180.96 undefined-1.48 undefined-1.58 undefined
20173.38 undefined-0.15 undefined-0.25 undefined
20161.05 undefined-2.43 undefined-2.59 undefined
20151.61 undefined-1.74 undefined-1.91 undefined
20141.74 undefined-1.88 undefined-1.98 undefined
20131.49 undefined-2.05 undefined-2.08 undefined
20125.99 undefined1.81 undefined1.83 undefined
20113.83 undefined-2.16 undefined-2.15 undefined
20103.64 undefined-2.74 undefined-2.64 undefined
20092.93 undefined-3.68 undefined-3.63 undefined
20083.64 undefined-3.98 undefined-5.61 undefined
20075.06 undefined-3.48 undefined-3.45 undefined
20063.38 undefined-4.76 undefined-5.05 undefined
20055.32 undefined-2.91 undefined-3.38 undefined
20042.69 undefined-4.72 undefined-5.37 undefined

DURECT business model

DURECT Corporation is a US pharmaceutical company specializing in the development and marketing of innovative drugs for chronic pain, neurological disorders, and metabolic disorders. They have a broad portfolio of products based on various technologies and platforms, including Parenteral Controlled Release (PCR), Transdermal Delivery Systems (TDS), and Oral Sustained Release (OSR). They have developed technologies such as PCR for slow drug release, TDS for drug administration through the skin, and OSR for sustained-release tablets. DURECT has partnerships with notable pharmaceutical companies such as Pfizer, Sandoz, Zogenix, and Janssen Pharmaceutica, allowing them to distribute their products in a wider market and expand internationally. Their goal is to continue strengthening their position as a leading company in the industry and expanding their product range. DURECT is one of the most popular companies on Eulerpool.com.

DURECT Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

DURECT Revenue by Segment

Segmente20222021202020192018
Collaborative Research and Development and Other Revenue13.2 M USD----
Product Revenue, Net6.08 M USD1.1 M USD---
Collaborative research and development and other revenue-6.33 M USD---
Collaborative research and development and other revenue--23.94 M USD18.13 M USD8.21 M USD
Product Revenue, Net--6.17 M USD11.44 M USD10.36 M USD
License Fees4 M USD4,000 USD---

DURECT Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

DURECT Revenue by Segment

DateEuropeJapanJAPANOther foreign countriesOther Foreign CountriesUnited States
202211.79 M USD1.49 M USD--557,000 USD5.45 M USD
20216.63 M USD-1.02 M USD642,000 USD-5.69 M USD
20201.39 M USD-1.17 M USD657,000 USD-26.89 M USD
20193.13 M USD1.48 M USD-2.13 M USD-22.83 M USD
20188.12 M USD978,000 USD-1.48 M USD-7.99 M USD

DURECT SWOT Analysis

Strengths

1. Established Market Presence: DURECT Corp has built a strong brand reputation and enjoys a significant market share within the pharmaceutical industry.

2. Robust Research and Development: The company has a dedicated R&D team focusing on continuous innovation and development of new drug delivery technologies.

3. Strong Intellectual Property Portfolio: DURECT Corp holds a diverse range of patents and intellectual property rights, providing a competitive advantage and barriers to entry for potential competitors.

Weaknesses

1. Dependence on Few Key Customers: DURECT Corp heavily relies on a limited number of major clients, which exposes the company to potential revenue fluctuations and loss of business if contracts are not renewed.

2. High Research and Development Costs: The extensive investment required for R&D activities puts financial strain on the company, making it vulnerable during periods of low profitability.

3. Limited Product Portfolio: DURECT Corp's product range is relatively limited in comparison to some of its competitors, which may restrict its market reach and growth potential.

Opportunities

1. Growing Demand for Drug Delivery Solutions: The increasing need for enhanced drug delivery methods presents an opportunity for DURECT Corp to expand its product offerings and capture a larger market share.

2. Collaborative Partnerships: Forming strategic alliances and partnerships with pharmaceutical companies or research institutions can facilitate knowledge exchange, cost-sharing, and broader market access.

3. Expansion into Emerging Markets: DURECT Corp can capitalize on the rising healthcare needs in developing countries by expanding its operations and establishing a presence in these markets.

Threats

1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous established players and new entrants vying for market share. DURECT Corp faces the risk of price wars and loss of customers to competitors.

2. Stringent Regulatory Environment: Compliance with stringent regulations and approval processes can lead to delays in product development and commercialization, increasing time-to-market and impacting profitability.

3. Technological Advances: Rapid advancements in drug delivery technologies by competitors may render DURECT Corp's existing solutions obsolete, necessitating continuous innovation to stay ahead.

DURECT Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

DURECT historical P/E ratio, EBIT multiple, and P/S ratio

DURECT shares outstanding

The number of shares was DURECT in 2023 — This indicates how many shares 26.256 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue DURECT earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates DURECT's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of DURECT’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating DURECT's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

DURECT stock splits

In DURECT's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for DURECT.

DURECT latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.17 -0.12  (30.8 %)2024 Q2
3/31/2024-0.22 -0.25  (-11.41 %)2024 Q1
12/31/2023-0.34 -0.1  (70.52 %)2023 Q4
9/30/2023-0.43 -0.14  (67.32 %)2023 Q3
6/30/2023-0.52 -0.42  (19.26 %)2023 Q2
3/31/2023-0.54 -0.47  (13.06 %)2023 Q1
12/31/2022-0.56 -0.46  (17.5 %)2022 Q4
9/30/2022-0.1 -0.1  (1.96 %)2022 Q3
6/30/2022-0.48 -0.5  (-5.04 %)2022 Q2
3/31/2022-0.54 -0.5  (8.09 %)2022 Q1
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the DURECT stock

Eulerpool World ESG Rating (EESG©)

50/ 100

🌱 Environment

55

👫 Social

51

🏛️ Governance

45

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees65
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

DURECT shareholders

%
Name
Stocks
Change
Date
6.91367 % Ingalls & Snyder LLC (Asset Management)2,146,002159,46412/31/2023
4.92912 % Asen (Scott R.)1,530,0001,530,0002/14/2024
3.45518 % The Vanguard Group, Inc.1,072,48926,42112/31/2023
1.66976 % Richmond Brothers, Inc.518,294518,29412/31/2023
1.15563 % Gagnon Securities LLC358,706101,93812/31/2023
1.07699 % BlackRock Institutional Trust Company, N.A.334,298-68612/31/2023
1.03109 % Beirne Wealth Consulting Services, LLC320,05138,74312/31/2023
0.77466 % Brown (James E.)240,45303/26/2024
0.76461 % Dalton Investments LLC237,334-87,66612/31/2023
0.75504 % Geode Capital Management, L.L.C.234,364-19,19112/31/2023
1
2
3
4
5
...
10

DURECT Executives and Management Board

Mr. James Brown66
DURECT President, Chief Executive Officer, Director (since 1998)
Compensation 1.51 M
Dr. Norman Sussman70
DURECT Chief Medical Officer
Compensation 849,681
Ms. Judy Joice66
DURECT Senior Vice President - Operations and Corporate Quality Assurance
Compensation 713,552
Ms. Gail Maderis65
DURECT Independent Chairman of the Board
Compensation 86,150
Dr. Terrence Blaschke80
DURECT Independent Director
Compensation 83,150
1
2
3

Most common questions regarding DURECT

What values and corporate philosophy does DURECT represent?

DURECT Corp represents values of innovation, dedication, and quality. With a strong corporate philosophy focused on improving patient outcomes, DURECT Corp strives to develop and deliver advanced pharmaceutical products and therapeutics. The company aims to address unmet medical needs by leveraging its expertise in drug delivery technologies. DURECT Corp emphasizes a patient-centric approach, fostering collaboration with healthcare professionals and leveraging partnerships to accelerate the development and commercialization of its products. By providing novel solutions and demonstrating a commitment to improving healthcare, DURECT Corp establishes itself as a leading player in the pharmaceutical industry.

In which countries and regions is DURECT primarily present?

DURECT Corp is primarily present in the United States, focusing on the development and commercialization of innovative pharmaceutical products.

What significant milestones has the company DURECT achieved?

DURECT Corp has achieved several significant milestones. The company successfully developed and gained regulatory approval for its proprietary drug delivery platform, the DURIN technology. This platform allows for controlled and sustained release of drugs, improving therapeutic outcomes. DURECT Corp also received FDA approval for its postoperative pain relief medication, Posimir, providing patients with a non-opioid alternative for pain management. Additionally, the company entered into strategic partnerships with pharmaceutical giants such as Gilead Sciences and Indivior, benefiting from their expertise and expanding its market reach. These achievements reflect DURECT Corp's commitment to innovation and its potential for future growth.

What is the history and background of the company DURECT?

DURECT Corp is a pharmaceutical company with a rich history and a strong background. Founded in 1998, the company is focused on developing innovative therapies that help improve the lives of patients. DURECT Corp has consistently demonstrated its commitment to research and development, aiming to address unmet medical needs. With a diverse portfolio of drug delivery technologies and proprietary formulations, the company has been successful in creating unique solutions in the pharmaceutical industry. DURECT Corp continues to collaborate with partners and regulatory agencies to bring its products to market, establishing a solid reputation for its dedication to advancing healthcare.

Who are the main competitors of DURECT in the market?

The main competitors of DURECT Corp in the market include pharmaceutical companies such as Pfizer, Merck & Co., Johnson & Johnson, and Novartis. These established industry leaders consistently compete with DURECT Corp in various segments of the pharmaceutical market. Despite facing competition, DURECT Corp strives to differentiate itself through its innovative drug delivery technologies and collaboration with other pharmaceutical companies. Through their unique product offerings and strategic partnerships, DURECT Corp aims to establish a significant presence and gain a competitive edge in the challenging pharmaceutical market landscape.

In which industries is DURECT primarily active?

DURECT Corp is primarily active in the pharmaceutical and healthcare industries.

What is the business model of DURECT?

The business model of DURECT Corp revolves around the development and commercialization of pharmaceutical products. DURECT Corp specializes in developing drug delivery technologies and formulation solutions. The company focuses on creating pharmaceutical products that enhance the therapeutic benefits, provide patient convenience, and improve safety profiles. DURECT Corp collaborates with pharmaceutical companies to develop and market their products, utilizing its proprietary technologies and expertise. By leveraging its innovative drug delivery technologies, DURECT Corp aims to improve the efficacy, safety, and compliance of various medications, thereby addressing unmet medical needs.

What is the P/E ratio of DURECT 2024?

The DURECT P/E ratio is -1.18.

What is the P/S ratio of DURECT 2024?

The DURECT P/S ratio is 3.96.

What is the AlleAktien quality score of DURECT?

The AlleAktien quality score for DURECT is 3/10.

What is the revenue of DURECT 2024?

The expected DURECT revenue is 8.22 M USD.

How high is the profit of DURECT 2024?

The expected DURECT profit is -27.54 M USD.

What is the business model of DURECT

DURECT Corp is an innovative biopharmaceutical company specializing in the development and manufacture of drug delivery systems and novel therapies. The company was founded in 1998 and is headquartered in Cupertino, California. DURECT Corp has two business segments: DURECT Pharmaceutical and LACTEL Absorbable Polymers. DURECT Pharmaceutical develops innovative drug delivery platforms that revolutionize the way medications can be administered. This includes depot formulations that allow for sustained release of medications over a longer period, enabling better patient compliance and therapy. LACTEL Absorbable Polymers is a leading developer of resorbable polymers used in medical devices, wound care, and pharmaceutical development. Regarding DURECT Corp's product offerings, there are several important medications that the company has developed. The medication POSIMIR is a depot formulation of bupivacaine used for pain relief after surgeries. It is approved in the United States and Canada and has the potential to revolutionize postoperative pain management. Another important medication from DURECT Corp is REMOXY, a depot formulation of oxycodone for the treatment of chronic pain. REMOXY is approved in the United States. DURECT Corp also has other medications in various stages of development, including DUR-928 for the treatment of liver and kidney diseases, POSIMIR-PHASE 3 for knee pain treatment, and DUR-100B, a new drug delivery system through the nasal mucosa. DURECT Corp's business model is based on collaboration with leading pharmaceutical companies worldwide to develop innovative drug delivery platforms and novel therapies. The company has partnerships with major pharmaceutical companies such as Pfizer, Sandoz, and Gilead to jointly develop and distribute medications. Through these partnerships, DURECT Corp can bring its medications to market more effectively and quickly, and expand its business. DURECT Corp also has a strong focus on research and development to develop innovative technologies and strategies to improve the way medications are administered. The company has acquired a wide range of patents and intellectual property to protect its developments and maintain market leadership in this field. Overall, DURECT Corp has built a strong business model that focuses on the development of innovative drug delivery systems and novel therapies. Through partnerships with leading pharmaceutical companies and a strong focus on research and development, the company has the potential to become a major player in the biopharmaceutical industry and enable better treatment and care for patients.

What is the DURECT dividend?

DURECT pays a dividend of 0 USD distributed over payouts per year.

How often does DURECT pay dividends?

The dividend cannot currently be calculated for DURECT or the company does not pay out a dividend.

What is the DURECT ISIN?

The ISIN of DURECT is US2666051048.

What is the DURECT WKN?

The WKN of DURECT is 564868.

What is the DURECT ticker?

The ticker of DURECT is DRRX.

How much dividend does DURECT pay?

Over the past 12 months, DURECT paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, DURECT is expected to pay a dividend of 0 USD.

What is the dividend yield of DURECT?

The current dividend yield of DURECT is .

When does DURECT pay dividends?

DURECT pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of DURECT?

DURECT paid dividends every year for the past 0 years.

What is the dividend of DURECT?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is DURECT located?

DURECT is assigned to the 'Health' sector.

Wann musste ich die Aktien von DURECT kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of DURECT from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did DURECT pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of DURECT in the year 2023?

In the year 2023, DURECT distributed 0 USD as dividends.

In which currency does DURECT pay out the dividend?

The dividends of DURECT are distributed in USD.

All fundamentals about DURECT

Our stock analysis for DURECT Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DURECT Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.